Patterns of treatment switching and healthcare resource utilization differences among real-world Medicare patients with metastatic pancreatic ductal adenocarcinoma who received first-line FOLFIRINOX

被引：0
|
作者：
Dieguez, Gabriela
Hirsch, Jared
Cockrum, Paul
Bhatt, Prachi
Tomicki, Samantha
Kim, George P.
机构：
[1] Milliman Inc, New York, NY USA
[2] Ipsen Biopharmaceut Inc, Crowley, TX USA
[3] George Washington Univ, Washington, DC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16286
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Real-World First-Line Treatment Patterns Among US Carcinoid Syndrome Patients
    Sun, Gordon H.
    Neary, Maureen P.
    Chang, Eunice
    Broder, Michael S.
    PANCREAS, 2015, 44 (02) : 359 - 360
  • [22] Real-world Impact of Age at Diagnosis on Treatment Patterns and Survival Outcomes of Patients with Metastatic Pancreatic Ductal Adenocarcinoma
    Elias, Rawad
    Cockrum, Paul
    Surinach, Andy
    Wang, Shu
    Chu, Bong Chul
    Shahrokni, Armin
    ONCOLOGIST, 2022, 27 (06): : 469 - 475
  • [23] Clinical outcomes of first-line chemotherapy in locally advanced and metastatic pancreatic adenocarcinoma patients: Real-world experience
    Umpawan, N.
    Termsinsuk, P.
    Kaosombatwattana, U.
    Akewanlop, C.
    Korphaisarn, K.
    ANNALS OF ONCOLOGY, 2023, 34 : S919 - S920
  • [24] REAL-WORLD HEALTHCARE RESOURCE UTILIZATION AND TOTAL COST OF CARE AMONG US MEDICARE PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA RECEIVING FIRST-LINE IBRUTINIB VS CHEMOIMMUNOTHERAPY
    Huang, Q.
    Emond, B.
    Lafeuille, M. H.
    Gupta, D.
    Lefebvre, P.
    Sundaram, M.
    Mato, A.
    VALUE IN HEALTH, 2020, 23 : S44 - S45
  • [25] Real-world treatment patterns and outcomes among patients with BRAF plus metastatic melanoma refractory to first-line immunotherapy
    Truong, T. G.
    Chandra, S.
    Connolly, L.
    Shah, R.
    Byrne, C.
    Tang, J.
    Eroglu, Z.
    ANNALS OF ONCOLOGY, 2023, 34 : S673 - S673
  • [26] Overall survival and treatment patterns among real-world patients with metastatic urothelial carcinoma treated with first-line therapy
    Simeone, Jason C.
    Nordstrom, Beth L.
    Patel, Ketan
    Klein, Alyssa B.
    Horne, Laura
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 : 102 - 102
  • [27] Real-world prognostic factors for survival among treated patients with metastatic pancreatic ductal adenocarcinoma
    Yu, Kenneth H.
    Ozer, Muhammet
    Cockrum, Paul
    Surinach, Andy
    Wang, Shu
    Chu, Bong Chul
    CANCER MEDICINE, 2021, 10 (24): : 8934 - 8943
  • [28] REAL-WORLD TREATMENT PATTERNS AND HEALTHCARE RESOURCE UTILIZATION (HRU) IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC)
    Bhanegaonkar, A.
    Gauthier, G.
    Kim, R.
    Vekeman, F.
    Dea, K.
    Robitaille, M. N.
    Moyneur, E.
    Liu, F. X.
    VALUE IN HEALTH, 2020, 23 : S84 - S84
  • [29] Comparison of treatment patterns, resource utilization, and cost of care in patients with metastatic pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine or FOLFIRINOX
    Kim, George P.
    Parisi, Monika F.
    Patel, Manish B.
    Pelletier, Corey L.
    Belk, Kathy W.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (05) : 559 - 565
  • [30] Assessing real-world survival outcomes of patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with first-line FOLFIRINOX compared to patients from a phase 1/2 trial treated with NALIRIFOX.
    Zhu, Xuelian
    Cockrum, Paul
    Shah, Bonny
    Parzynski, Craig
    Garawin, Tamer
    Maxwell, Fiona
    Surinach, Andy
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345